Sbi Securities Co., Ltd. Astria Therapeutics, Inc. Transaction History
Sbi Securities Co., Ltd.
- $3.48 Trillion
- Q2 2025
A detailed history of Sbi Securities Co., Ltd. transactions in Astria Therapeutics, Inc. stock. As of the latest transaction made, Sbi Securities Co., Ltd. holds 1 shares of ATXS stock, worth $12. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1
Previous 1
-0.0%
Holding current value
$12
Previous $5,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding ATXS
# of Institutions
109Shares Held
49.3MCall Options Held
6.6KPut Options Held
0-
Perceptive Advisors LLC New York, NY6.49MShares$78.4 Million1.53% of portfolio
-
Vestal Point Capital, LP New York, NY4.52MShares$54.7 Million1.28% of portfolio
-
Fcpm Iii Services B.V. Naarden, P74.11MShares$49.7 Million6.34% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.55MShares$43 Million5.84% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$42.5 Million0.0% of portfolio
About Astria Therapeutics, Inc.
- Ticker ATXS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,178,000
- Market Cap $184M
- Description
- Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...